Medical treatment of pituitary adenomas;TRAITEMENTS MEDICAMENTEUX DES ADENOMES HYPOPHYSAIRES

Revue du Praticien

Volumn 46, Issue 12, 1996, Pages 1509-1513

  Chanson, Philippe ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; SOMATOSTATIN; THYROTROPIN; ANTINEOPLASTIC AGENT; BROMOCRIPTINE; CYCLOPEPTIDE; DRUG DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT;

ACROMEGALY; DRUG EFFICACY; GALLSTONE; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; INTRAMUSCULAR DRUG ADMINISTRATION; SHORT SURVEY; SUBCUTANEOUS DRUG ADMINISTRATION; ADENOMA; ARTICLE; HYPOPHYSIS TUMOR; TREATMENT OUTCOME;

ADENOMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; BROMOCRIPTINE; DOPAMINE AGONISTS; HUMANS; OCTREOTIDE; PEPTIDES, CYCLIC; PITUITARY NEOPLASMS; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 0030014529     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (19)

1. Chanson P, Schaison G. Pathologie de la prolactine. In: Mauvais-Jarvis P (ed). Médecine de la reproduction, gynécologie endocrinienne. Paris: Flammarion Médecine-Sciences, 1996 (sous presse).
2. Molitch ME. Prolactinoma. In: Melmed S (ed). The pituitary, Blackwell. Cambridge: Science Inc. 1995: 136-86.
3. Klibanski A, Zervas NT. Diagnosis and management of hormone-secreting pituitary adenomas. N Engl J Med 1991; 324: 822-31.
4. Vance ML, Thorner MO. Prolactin: hyperprolactinemic syndromes and management.In: De Groot L (ed). Endocrinology. Philadelphie: WB Saunders Co, 1995: 394-405.
5. Bevan JS, Webster J, Burke C, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992; 13: 220-40.
6. Krupp P, Monka C. Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 1987; 65: 823-7.
7. Kupersmith MJ, Rosenberg C, Kleinberg D. Visual loss in pregnant women with pituitary adenomas. Ann Intern Med 1994; 121: 473-7.
8. Beckers A, Petrossians P, Abs R et al. Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases. J Clin Endocrinol Metab 1992; 75: 275-80.
9. Vilar L, Burke CW. Quinagolide efficacy and tolerability in hyperprolactinemic patients who are resistant or intolerant of bromocriptine. Clin Endocrinol (Oxf) 1994; 41: 821-6.
10. Webster J, Piscitelli G, Polli A et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994; 331: 904-9.
11. Warnet A. Acromégalie. Editions Techniques. Encycl Med Chir (Paris-France), Endocrinologie-Nutrition 10-018-A-10, 1993: 8 p.
12. Chanson P, Timsit J, Harris AG. Octréotide, analogue de la somatostatine. Propriétés pharmacologiques et applications thérapeutiques dans les tumeurs endocriniennes hypophysaires. Presse Med 1993; 22: 2009-16.
13. Sassolas G, Harris AG, James-Deidier A et al. Long-term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. J Clin Endocrinol Metab 1990; 71: 391-7.
14. Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch Intern Med 1991; 151: 1573-8.
15. Heron I, Thomas F, Dero M et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 1993; 76: 721-7.
16. Morange I, De Boivilliers F, Chanson P et al. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab 1994; 79: 145-51.
17. Boucekkine C, Catus F, Blumberg-Tick J, Pholsena M, Chanson P, Schaison G. Traitement de l'acromégalie par un nouvel agoniste de la somatostatine, le lanréotide à action prolongée. Ann Endocrinol 1994; 55: 261-9.
18. Chanson P, Weintraub BD, Harris AG. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 1993; 119: 236-40.
19. Chanson P. Adénomes hypophysaires gonadotropes. Intérêt physiopathologique, diagnostique et thérapeutique des analogues de la GnRH et des autres peptides hypothalamiques. Rev F Endocrinol Clin 1995; 36: 193-201.